Trial Participants by Prevention Research Area, 2015
- Released in
Greater efforts must be made to include key populations in this crucial process for the HIV prevention response to be truly impactful.
AIDS Vaccine Advocacy Coalition (AVAC)
2016-17: A Percolating Pipeline
- Released in
In addition to the introduction of oral-TDF based PrEP and the open-lable extension studies of the vaginal dapivirine ring, there are a number of efficacy trials planned or underway.
Introduction to Long-Acting Injectables
- Released in
This infographic details the process for developing long-acting injectables for PrEP and treatment.
HIV Prevention Research and Development Funding Trends, 2000–2014: Investing in Innovation in an Evolving Global Health and Development Landscape
- Released in
The HIV Vaccines and Microbicides Resource Tracking Working Group documents biomedical HIV prevention research and development spending for the calendar year 2014.
Global Investment in HIV Cure Research and Development in 2016: Funding for a Cure Remains a Priority
- Released in
Antiretroviral treatment (ART) has radically changed the face of HIV infection, from a lethal disease into a manageable chronic condition.
Oral Pre-exposure Prophylaxis – Putting a New Choice in Context
- Released in
Oral PrEP is an additional HIV prevention option for individuals at substantial risk of HIV exposure that will be effective as part of a comprehensive response to HIV.
Pre-Exposure Prophylaxis (PrEP) by the Numbers: Efficacy, regulatory approval and more
- Released in
PrEP works if you take it. The figures on this graphic show the relationship between PrEP efficacy and adherence and the status of regulatory action on PrEP worldwide. It also shows other potential new formulations of ARV-based prevention being evaluated as additional options in the future.
HIV Prevention Research and Development Investments, 2017: Investing to End the Epidemic
- Released in
Flat and/or reduced funding for HIV/AIDS and other global health issues threatens to roll back progress worldwide. There is belated and widespread acknowledgment of a prevention crisis that can only be addressed by taking today’s tools to scale while researching new ones. Given this backdrop, the report is a powerful advocacy tool. This year’s report notes troubling trends in investment flows for biomedical HIV prevention at a moment of major promise in the research landscape.
AVAC Report 2018: No Prevention, No End!
- Released in
AVAC's 2018 annual state of the field report, No Prevention, No End! looks at today's prevention crisis and offers context, analysis and strategy to turn that crisis around.